PE68898A1 - Composiciones antihongo con biodisponibilidad mejorada - Google Patents
Composiciones antihongo con biodisponibilidad mejoradaInfo
- Publication number
- PE68898A1 PE68898A1 PE1997000400A PE00040097A PE68898A1 PE 68898 A1 PE68898 A1 PE 68898A1 PE 1997000400 A PE1997000400 A PE 1997000400A PE 00040097 A PE00040097 A PE 00040097A PE 68898 A1 PE68898 A1 PE 68898A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- triazol
- preference
- fenil
- improved bioavailability
- Prior art date
Links
- 239000012871 anti-fungal composition Substances 0.000 title 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 abstract 1
- -1 2,4-DIFLUOROPHENYL Chemical class 0.000 abstract 1
- 241000228212 Aspergillus Species 0.000 abstract 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000004141 Sodium laurylsulphate Substances 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000003429 antifungal agent Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
CARACTERIZADAS PORQUE COMPRENDEN: (A) UN AGENTE ANTIFUNGICO DE TRIAZOL, QUE ES (-)-(2R-CIS)-4-[4-[4-[4-[[-5-(2,4-DIFLUOROFENIL)TETRAHIDRO-5-(1H-1,2,4-TRIAZOL-1-ILMETIL)FURAN-3-IL]METOXI]FENIL]-1-PIPERAZINIL]FENIL]-2,4-DIHIDRO-2-[(S)-1-ETIL-2(S)-HIDROXIPROPIL]-3H-1,2,4-TRIAZOL-3-ONA, DE PREFERENCIA DE 18% A 50% EN PESO; (B) POR LO MENOS UN SURFACTANTE NO IONICO QUE ES DE PREFERENCIA UN BLOQUE COPOLIMERO DE OXIDO DE ETILENO Y OXIDO DE PROPILENO, DE PREFERENCIA DE 9% A 50% EN PESO; (C) UN DILUYENTE QUE ES CELULOSA MICROCRISTALINA, DE PREFERENCIA DE 12% A 60% EN PESO; ADICIONALMENTE PUEDE COMPRENDER: (D) DE 4% A 10% EN PESO DE CROSCARMELOSA DE SODIO; (E) DE 3% A 6% EN PESO DE POLIVINILPIRROLIDONA; (F) DE 0,3% A 1,5% EN PESO DE ESTEARATO DE MAGNESIO; (G) DE 3% A 8% EN PESO DE LAURIL SULFATO DE SODIO. EN ESTAS COMPOSICIONES LA INCLUSION DEL SURFACTANTE MEJORA LA BIODISPONIBILIDAD Y LA ACTIVIDAD ANTIFUNGICA, SIENDO UTILES EN EL TRATAMIENTO CONTRA HONGOS OPORTUNISTAS TALES COMO ASPERGILLUS, CANDIDA O CRYPTOCCOCUS, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65532996A | 1996-05-24 | 1996-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE68898A1 true PE68898A1 (es) | 1998-11-10 |
Family
ID=24628452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1997000400A PE68898A1 (es) | 1996-05-24 | 1997-05-21 | Composiciones antihongo con biodisponibilidad mejorada |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0914127B1 (es) |
| JP (1) | JP3366648B2 (es) |
| KR (1) | KR100307427B1 (es) |
| CN (1) | CN1121860C (es) |
| AR (1) | AR007250A1 (es) |
| AT (1) | ATE213632T1 (es) |
| AU (1) | AU719109B2 (es) |
| BR (1) | BR9711167A (es) |
| CA (1) | CA2255663C (es) |
| CO (1) | CO4840511A1 (es) |
| CZ (1) | CZ293586B6 (es) |
| DE (1) | DE69710729T2 (es) |
| ES (1) | ES2169440T3 (es) |
| HK (1) | HK1017855A1 (es) |
| HU (1) | HU221371B1 (es) |
| ID (1) | ID16956A (es) |
| IL (1) | IL126979A (es) |
| MY (1) | MY118988A (es) |
| NO (1) | NO316997B1 (es) |
| NZ (1) | NZ332699A (es) |
| PE (1) | PE68898A1 (es) |
| PL (1) | PL188401B1 (es) |
| RU (1) | RU2207119C2 (es) |
| SK (1) | SK281818B6 (es) |
| TR (1) | TR199802424T2 (es) |
| TW (1) | TW504390B (es) |
| WO (1) | WO1998007429A2 (es) |
| ZA (1) | ZA974428B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2157731B1 (es) * | 1998-07-21 | 2002-05-01 | Liconsa Liberacion Controlada | Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. |
| ATE329579T1 (de) | 1999-11-12 | 2006-07-15 | Abbott Lab | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| KR100596257B1 (ko) * | 2001-01-26 | 2006-07-03 | 쉐링 코포레이션 | 스테롤 흡수 억제제를 포함하는 조성물, 및 페록시솜 증식인자-활성화 수용체 활성화제와 스테롤 흡수 억제제를 포함하는 조성물 및 조합물 |
| US20050163839A1 (en) * | 2003-01-29 | 2005-07-28 | Sun Pharmaceutical Industries Limited | Oral controlled release pharmaceutical composition containing metaxalone as active agent |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| CN103379917B (zh) | 2010-11-01 | 2016-10-12 | 梅琳塔治疗公司 | 药物组合物 |
| RU2450807C1 (ru) * | 2011-05-11 | 2012-05-20 | Общество с ограниченной ответственностью фирма "Вита" | Стабилизированный фармацевтический состав с противогрибковым действием |
| CN103845292A (zh) * | 2012-11-29 | 2014-06-11 | 正大天晴药业集团股份有限公司 | 泊沙康唑微丸及其制备方法 |
| US9763934B2 (en) * | 2014-03-05 | 2017-09-19 | Professional Compounding Centers Of America | Synergistic effect of poloxamer-based composition and itraconazole on fungus and yeast |
| TR201620462A2 (tr) | 2016-12-31 | 2018-07-23 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4791111A (en) * | 1985-12-23 | 1988-12-13 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties |
| US5039676A (en) * | 1990-05-11 | 1991-08-13 | Schering Corporation | Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof |
| DK0736030T3 (da) * | 1993-12-21 | 2001-10-29 | Schering Corp | Fungicide tetrahydrofuraner |
-
1997
- 1997-05-21 SK SK1608-98A patent/SK281818B6/sk not_active IP Right Cessation
- 1997-05-21 TR TR1998/02424T patent/TR199802424T2/xx unknown
- 1997-05-21 ID IDP971708A patent/ID16956A/id unknown
- 1997-05-21 WO PCT/US1997/019388 patent/WO1998007429A2/en active IP Right Grant
- 1997-05-21 AT AT97949341T patent/ATE213632T1/de not_active IP Right Cessation
- 1997-05-21 TW TW086106780A patent/TW504390B/zh not_active IP Right Cessation
- 1997-05-21 PL PL97330480A patent/PL188401B1/pl not_active IP Right Cessation
- 1997-05-21 DE DE69710729T patent/DE69710729T2/de not_active Expired - Lifetime
- 1997-05-21 PE PE1997000400A patent/PE68898A1/es not_active Application Discontinuation
- 1997-05-21 ZA ZA9704428A patent/ZA974428B/xx unknown
- 1997-05-21 ES ES97949341T patent/ES2169440T3/es not_active Expired - Lifetime
- 1997-05-21 IL IL12697997A patent/IL126979A/xx not_active IP Right Cessation
- 1997-05-21 CZ CZ19983790A patent/CZ293586B6/cs not_active IP Right Cessation
- 1997-05-21 HU HU9904265A patent/HU221371B1/hu not_active IP Right Cessation
- 1997-05-21 AU AU59399/98A patent/AU719109B2/en not_active Ceased
- 1997-05-21 RU RU98123611/14A patent/RU2207119C2/ru not_active IP Right Cessation
- 1997-05-21 EP EP97949341A patent/EP0914127B1/en not_active Expired - Lifetime
- 1997-05-21 BR BR9711167A patent/BR9711167A/pt not_active IP Right Cessation
- 1997-05-21 CN CN97196513A patent/CN1121860C/zh not_active Expired - Fee Related
- 1997-05-21 KR KR1019980709501A patent/KR100307427B1/ko not_active IP Right Cessation
- 1997-05-21 JP JP50544798A patent/JP3366648B2/ja not_active Expired - Fee Related
- 1997-05-21 CO CO97027673A patent/CO4840511A1/es unknown
- 1997-05-21 NZ NZ332699A patent/NZ332699A/xx not_active IP Right Cessation
- 1997-05-21 CA CA002255663A patent/CA2255663C/en not_active Expired - Fee Related
- 1997-05-22 MY MYPI97002234A patent/MY118988A/en unknown
- 1997-05-22 AR ARP970102173A patent/AR007250A1/es active IP Right Grant
-
1998
- 1998-11-23 NO NO19985447A patent/NO316997B1/no not_active IP Right Cessation
-
1999
- 1999-07-13 HK HK99103016A patent/HK1017855A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE68898A1 (es) | Composiciones antihongo con biodisponibilidad mejorada | |
| De Brabander et al. | The activity of ketoconazole in mixed cultures of leukocytes and Candida albicans | |
| Oakley et al. | In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp | |
| Barchiesi et al. | In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles | |
| US5591397A (en) | Double redox system for disinfecting contact lenses | |
| ES8505364A1 (es) | Un procedimiento para la preparacion 1-imidazoles y 1h-1, 2, 4-triazoles | |
| ES2064067T3 (es) | Procedimiento de tratamiento fungicida foliar por medio de un triazol y composicion fungicida para poner en practica el procedimiento. | |
| PE20051051A1 (es) | Compuestos de triazol como antagonistas de la vasopresina | |
| Anaissie et al. | Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis | |
| IL152179A0 (en) | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids | |
| Odds et al. | Effects of azole antifungals in vitro on host/parasite interactions relevant to Candida infections | |
| PE17897A1 (es) | Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano | |
| PE17997A1 (es) | Formulacion transdermica en parche del 3-[3-(hexiltio-1,2,5-tiadiazol-4-ilo]-1,2,5,6 tetrahidro-1-metil piridina | |
| KR890002120A (ko) | 살균제 조성물 | |
| MY107016A (en) | Use of certain triazoles to protect materials from fungal attack, articles and compositions | |
| AR001834A1 (es) | Empleo de una combinación de productos activos en la fabricación del cuero agente microbicida que contiene dichos productos activos procedimiento parala protección de pieles animales y del cuero cont ra el ataque microbiano empleo de dicha combinación para la obtención de agentes | |
| Arias et al. | In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents: Empfindlichkeit in vitro von 545 Candida‐Isolaten für vier Antimyzetika | |
| ES2126299T3 (es) | Nuevo producto de combinacion que comprende un agente antifungico y crotamiton como potenciador de la actividad del agente antifungico, y composiciones dermatologicas y/o cosmeticas que lo contienen. | |
| Singh et al. | Therapeutic value of keratoplasty in keratomycosis: an experimental study | |
| KR970014568A (ko) | 살진균 활성 화합물의 배합물 | |
| TR200200097T2 (tr) | Yeni antimikotikler, fungizidler, bunların üretimine ilişkin metotlar. | |
| Jeffries et al. | Self-penetration by the mycoparasite Dimargaris cristalligena | |
| Altınkurt et al. | The Effects of Honeybee (Apis mellifera) Venom on the Blood Pressure and the Infestinal Motility of the Guinea—pig | |
| UY25908A1 (es) | Composiciones oftálmicas que contienen ciclosporina, un surfactante y un vehículo acuoso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |